Acadia Pharmaceuticals Inc (NASDAQ: ACAD) kicked off on Tuesday, up 6.85% from the previous trading day, before settling in for the closing price of $22.2. Over the past 52 weeks, ACAD has traded in a range of $13.40-$26.65.
While this was happening, its average annual earnings per share was recorded -41.76%. With a float of $167.85 million, this company’s outstanding shares have now reached $169.15 million.
Acadia Pharmaceuticals Inc (ACAD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acadia Pharmaceuticals Inc is 0.79%, while institutional ownership is 100.55%. The most recent insider transaction that took place on Nov 10 ’25, was worth 670,983. Before that another transaction happened on Sep 15 ’25, when Company’s EVP, CHIEF FINANCIAL OFFICER sold 3,498 for $23.65, making the entire transaction worth $82,728. This insider now owns 43,447 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.86 earnings per share (EPS), higher than consensus estimate (set at 0.22) by 0.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -41.76% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Take a look at Acadia Pharmaceuticals Inc’s (ACAD) current performance indicators. Last quarter, stock had a quick ratio of 2.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.83. Likewise, its price to free cash flow for the trailing twelve months is 20.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.55, a number that is poised to hit 0.14 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Let’s dig in a bit further. During the last 5-days, its volume was 1.86 million. That was inferior than the volume of 2.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 71.75%.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 57.90%, which indicates a significant decrease from 96.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.01 in the past 14 days, which was higher than the 0.79 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.51, while its 200-day Moving Average is $20.60. However, in the short run, Acadia Pharmaceuticals Inc’s stock first resistance to watch stands at $24.37. Second resistance stands at $25.01. The third major resistance level sits at $26.20. If the price goes on to break the first support level at $22.54, it is likely to go to the next support level at $21.35. The third support level lies at $20.71 if the price breaches the second support level.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
The company with the Market Capitalisation of 4.01 billion has total of 169,182K Shares Outstanding. Its annual sales at the moment are 957,800 K in contrast with the sum of 226,450 K annual income. Company’s last quarter sales were recorded 278,630 K and last quarter income was 71,780 K.
